MRS monitoring of tumor tCho or PME levels in patients undergoing treatment with ChKα-targeted drugs may facilitate non-invasive assessment of tumor response for more precise treatment monitoring and dynamic adjustment of the treatment plan. This evidence concerns the gene CHKA and neoplasm.